230

GLOBAL BURDEN OF YOUNG-ONSET GASTRIC CANCER: A SYSTEMATIC TREND ANALYSIS OF THE GLOBAL BURDEN OF DISEASE STUDY 2019

Date
May 18, 2024

Objectives: While gastric cancer is declining overall, the global trend of young-onset (<40 years) gastric cancer remains uncertain. In this study we assessed the temporal trends of young-onset gastric cancer compared to late-onset gastric cancer (≥40 years).
Methods: We extracted cross-sectional data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. The burden of disease from 1990 to 2019 was assessed through incidence and mortality rates classified by global, national, and regional levels, and stratified by socio-demographic indexes (SDI), age, and sex groups. Joinpoint regression analysis was used to identify specific years with significant changes using a Monte Carlo Permutation method. The correlation between annual average percentage change (AAPC) in incidence and mortality with each country's average SDI was tested by Pearson’s Test.
Results: The global incidence rate of young-onset gastric cancer decreased from 2.20 per 100,000 in 1990 to 1.65 in 2019 with AAPC of -0.95 (95% confidence interval [CI]: -1.25 to -0.65; P<0.001). Late-onset cancer incidence also decreased from 59.53 per 100,000 in 1990 to 41.26 in 2019 (AAPC: -1.23; 95%CI: -1.39 to -1.06, P<0.001). Despite an overall decreasing trend, the incidence rate significantly increased from 2015 to 2019 for young-onset cancer (annual percentage change [APC]: 1.39; 95% CI: 0.06 to 2.74; P=0.041), whereas no upward trend was observed in late-onset cancer. Mortality rates of young- and late-onset cancer both exhibited a significant decline from 1990 to 2019 (AAPC: -1.82; 95% CI: -2.15 to -1.56; P<0.001 and AAPC: -1.69, 95%CI: -1.79 to -1.59; P<0.001; Figure 1). The male-to-female rate ratio for incidence and mortality in both age groups have been increasing significantly since 1990. While countries with high SDI have had a significant decline in the incidence of late-onset gastric cancer (slope of AAPC change: -0.20, P=0.004), the decline in young-onset cancer was not significant (slope of AAPC change: -0.11, P=0.130; Figure 2).
Conclusions: While the global incidence and mortality rates of both young- and late-onset gastric cancer have decreased since 1990., the incidence of young-onset cancer has demonstrated a significant upward trend since 2015. There were higher rates of decline in male and high SDI countries compared to females and low SDI countries, highlighting important disparities. These findings could help to inform future strategies in preventing gastric cancer, particularly in younger individuals.
<b>Figure 1 </b>Joinpoint regression analysis comparison of global young-onset and late-onset gastric cancer incidence rate(A and B), and mortality rate(C and D), from 1990 to 2019.

Figure 1 Joinpoint regression analysis comparison of global young-onset and late-onset gastric cancer incidence rate(A and B), and mortality rate(C and D), from 1990 to 2019.

<b>Figure 2 </b>Correlation of average SDI with AAPC of incidence and mortality rate in young and late-onset gastric cancer (each dot represents a single country)

Figure 2 Correlation of average SDI with AAPC of incidence and mortality rate in young and late-onset gastric cancer (each dot represents a single country)

Presenter

Speakers

Speaker Image for Monika Laszkowska
Memorial Sloan Kettering Cancer Center
Speaker Image for Ann Zauber
Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics
Speaker Image for Wai Keung Leung
University of Hong Kong Li Ka Shing Faculty of Medicine

Tracks

Related Products

Thumbnail for GLOBAL HEALTH INEQUALITY ANALYSIS OF PREMATURE MORTALITY RELATED TO PEPTIC ULCER DISEASE: A SYSTEMATIC ANALYSIS BASED ON GLOBAL BURDEN OF DISEASE
GLOBAL HEALTH INEQUALITY ANALYSIS OF PREMATURE MORTALITY RELATED TO PEPTIC ULCER DISEASE: A SYSTEMATIC ANALYSIS BASED ON GLOBAL BURDEN OF DISEASE
OBJECTIVES: Despite the declining incidence and mortality rates of peptic ulcer disease (PUD) over the past three decades, there remains an uneven distribution of disease burden in countries with varying sociodemographic levels…
Thumbnail for CMS COVERAGE DECISION: IMPLICATIONS FOR COST-EFFECITVENESS OF BLOOD-BASED COLORECTAL CANCER SCREENING
CMS COVERAGE DECISION: IMPLICATIONS FOR COST-EFFECITVENESS OF BLOOD-BASED COLORECTAL CANCER SCREENING
A blood-based colorectal cancer (CRC) screening test may increase screening participation. However, blood-based screening tests may be less effective than current guideline-endorsed options…
Thumbnail for VONOPRAZAN-BASED DUAL AND TRIPLE THERAPY VERSUS BISMUTH-BASED QUADRUPLE THERAPY AS FIRST-LINE THERAPY FOR HELICOBACTER PYLORI INFECTION IN CHINA: A THREE-ARMED, RANDOMIZED CLINICAL TRIAL
VONOPRAZAN-BASED DUAL AND TRIPLE THERAPY VERSUS BISMUTH-BASED QUADRUPLE THERAPY AS FIRST-LINE THERAPY FOR HELICOBACTER PYLORI INFECTION IN CHINA: A THREE-ARMED, RANDOMIZED CLINICAL TRIAL
BACKGROUND AND AIM: We aimed to compare efficacy of vonoprazan-based therapies and bismuth-based quadruple therapy as first-line treatment for _Helicobacter pylori_ (_H. pylori_) infection in Southern China, where high primary resistance rates of clarithromycin and levofloxacin (>30%) exist…
Thumbnail for ASSOCIATION BETWEEN GLYCEMIC CONTROL AND COLORECTAL ADENOMA AND CANCER RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A POPULATION-BASED COHORT STUDY
ASSOCIATION BETWEEN GLYCEMIC CONTROL AND COLORECTAL ADENOMA AND CANCER RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A POPULATION-BASED COHORT STUDY
BACKGROUND: Whether glycemic control influences the risk of colonic adenoma and colorectal cancer (CRC) development is unknown…